Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,956 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hormone Clear all
Not listed Phase 2 Interventional

Pulsatile GnRH in Anovulatory Infertility

NCT00383656
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Amenorrhea, Kallmann's Syndrome
Interventions
GnRH, Pump
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Jul 22, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Bone Response to Soy Isoflavones in Women

NCT00043745
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
Soy isoflavones, Extract tablets
Dietary Supplement
Lead sponsor
Iowa State University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
2
States / cities
Davis, California • Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Jul 22, 2026, 9:50 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

NCT00264927
View directory record Official record
Conditions
Inappropriate ADH Syndrome, Hyponatremia
Interventions
SR121463B
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 9, 2008 · Synced Jul 22, 2026, 9:50 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

NCT01137682
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
4
States / cities
Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jul 22, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Results available

Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients

NCT02733588
View directory record Official record
Conditions
Hypoglycemia, Complications of Bariatric Procedures
Interventions
G-Pump™ (glucagon infusion)
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Jul 22, 2026, 9:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Pregnancy-associated Hormones on THC Metabolism in Women

NCT04374773
View directory record Official record
Conditions
Pregnancy Related, Cannabis Use
Interventions
Dronabinol
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Results available

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

NCT03007979
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
Interventions
Palbociclib, Letrozole, Fulvestrant, Optional research biopsy, Goserelin, Research blood draw, Circulating tumor cell blood draw, Tumor biopsy (optional)
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
St Louis, Missouri • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Jul 22, 2026, 9:50 PM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

NCT02820961
View directory record Official record
Conditions
Breast Cancer, Estrogen Receptor Positive Breast Cancer
Interventions
entinostat, exemestane
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Jul 22, 2026, 9:50 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Menstrual Cycle TMS Plasticity Pilot

NCT07180654
View directory record Official record
Conditions
Cortical Activation
Interventions
transcranial magnetic stimulation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
20 Years to 40 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jul 22, 2026, 9:50 PM EDT
Completed Phase 2 Interventional

Nutrients and Hormones: Effects in Boys With Disordered Growth

NCT00139451
View directory record Official record
Conditions
Constitutional Growth Delay, Nutrition Disorders, Growth Disorders
Interventions
Pediasure, GH
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 10 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Jul 22, 2026, 9:50 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

NCT01415960
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Drug
Lead sponsor
GP-Pharm
Industry
Eligibility
18 Years and older · Male only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
San Diego, California • Daytona Beach, Florida • Ocala, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 22, 2026, 9:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Age-Related Changes in Stress Hormone Regulation

NCT00018369
View directory record Official record
Conditions
Physiological Processes, Aging
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Jul 22, 2026, 9:50 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

NCT05551117
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
Interventions
vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 22, 2026, 9:50 PM EDT
Completed Not applicable Interventional Results available

The Gender-Sex Hormone Interface With Craving & Stress-Related Changes in Smoking

NCT01576874
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Oxytocin, placebo
Drug
Lead sponsor
Kevin Gray, MD
Other
Eligibility
18 Years to 45 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Jul 22, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Results available

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

NCT01533246
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
linsitinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Jul 22, 2026, 9:50 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Everolimus Beyond Progression

NCT02269670
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
everolimus, anastrozole, letrozole, tamoxifen citrate, fulvestrant, megestrol acetate
Drug
Lead sponsor
Emory University
Other
Eligibility
19 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Jul 22, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Results available

Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00488982
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Docetaxel and GM-CSF
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Jul 22, 2026, 9:50 PM EDT
Completed Phase 3 Interventional

ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)

NCT00231946
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
VP4896
Drug
Lead sponsor
Voyager Pharmaceutical Corporation
Industry
Eligibility
60 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
55
States / cities
Peoria, Arizona • Tucson, Arizona • Fresno, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2007 · Synced Jul 22, 2026, 9:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Multi-ingredient Supplement for Strength and Power

NCT01971723
View directory record Official record
Conditions
Supplement
Interventions
T+ Supplement, Placebo
Other
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Jul 22, 2026, 9:50 PM EDT
Recruiting Phase 2 Interventional

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

NCT06224673
View directory record Official record
Conditions
HER2 Low Breast Carcinoma, Triple Negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma
Interventions
ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride
Drug · Procedure
Lead sponsor
Laura Huppert, MD, BA
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 9:50 PM EDT
Recruiting Phase 1Phase 2 Interventional

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366
View directory record Official record
Conditions
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer
Interventions
Rina-S, Carboplatin, Bevacizumab, Pembrolizumab
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 9:50 PM EDT
Terminated Phase 2 Interventional Results available

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

NCT01253642
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Biopsy of Prostate, Docetaxel, Laboratory Biomarker Analysis, Phenelzine Sulfate
Procedure · Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Jul 22, 2026, 9:50 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

N-Terminal Pro-brain Natriuretic Peptide Hormone and Persistent Pulmonary Hypertension

NCT00443859
View directory record Official record
Conditions
Persistent Pulmonary Hypertension of Newborn
Interventions
Not listed
Lead sponsor
Christiana Care Health Services
Other
Eligibility
Up to 6 Months
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Newark, Delaware • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Jul 22, 2026, 9:50 PM EDT
Withdrawn Phase 2 Interventional

The Effect of Vitamin C on Growth Hormone Secretion

NCT01537094
View directory record Official record
Conditions
Obese, Disorder of Vitamin C, Growth Hormone Secretion Abnormality
Interventions
Placebo, Vitamin C 250 mg once daily, Vitamin C 1,000 mg once daily
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Jul 22, 2026, 9:50 PM EDT